SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Taisho Pharmaceutical Holdings Co., Ltd. (TAISF) 当前追踪市盈率 (P/E) 为 0.3. 追踪盈利收益率为 400.00%. PEG 0.01 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
- VALUE (100/100, 通过) — 市盈率低于市场平均水平 (0.3); PEG ≤ 1.0 — Peter Lynch 低估标准 (0.01); 盈利收益率超过债券收益率 (400.00%).
- PEG 比率 0.01 — 低于1.0表明股票相对于其盈利增长率被低估（Peter Lynch 标准）。
- 追踪盈利收益率 400.00% — 超过典型债券收益率（约4.3%），使股票相对固定收益更具吸引力。
SharesGrow 综合评分： 73/100 其中 3/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — TAISF
估值倍数
P/E (TTM)0.3
前瞻 P/EN/A
PEG 比率0.01
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.02
EV/EBITDA0.0
每股数据
EPS (TTM)$231.42
每股账面价值$0.00
每股营收$3,671.44
每股自由现金流$0.00
收益率与内在价值
盈利收益率400.00%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2013 |
$403.07 |
$295.97B |
$32.69B |
11% |
| 2014 |
$302.42 |
$290.49B |
$24.53B |
8.4% |
| 2015 |
$277.59 |
$289.96B |
$22.47B |
7.8% |
| 2016 |
$359.92 |
$279.75B |
$28.78B |
10.3% |
| 2017 |
$396.20 |
$280.14B |
$31.68B |
11.3% |
| 2018 |
$608.22 |
$261.37B |
$48.59B |
18.6% |
| 2019 |
$252.44 |
$288.72B |
$20.17B |
7% |
| 2020 |
$166.63 |
$282.04B |
$13.32B |
4.7% |
| 2021 |
$160.93 |
$268.2B |
$13.12B |
4.9% |
| 2022 |
$231.42 |
$301.38B |
$19B |
6.3% |
